Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
AssigneeQuanterix Corporation
InventorsDavid Wilson, David C. Duffy, David Hanlon, David Okrongly
Life of this patent
Estimating the term…
Abstract
The present invention generally relates, in some embodiments, to methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy.
Claims27
A method of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer, following a radical prostatectomy, comprising:
- performing an assay on a sample obtained from the patient following the radical prostatectomy to determine a measure of the concentration of prostate specific antigen (PSA) in the sample, wherein the concentration of PSA in the sample is less than about 50 pg/mL;
- and
- determining the patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following the radical prostatectomy based at least in part on the measured concentration of PSA in the sample, wherein determining the patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment does not require measurement of a change in concentration of PSA measured in multiple patient samples as a function of time elapsed after the radical prostatectomy.
2-3. (canceled)
A method of determining a patient's prognosis for recurrence of prostate cancer, and/or determining a course of treatment for prostate cancer following a radical prostatectomy, comprising:
- performing an assay on a sample obtained from the patient following the radical prostatectomy to determine a measure of the concentration of prostate specific antigen (PSA) in the sample, wherein the sample is obtained from the patient within 6 months following the radical prostatectomy;
- and
- determining the patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy based at least in part on the concentration of PSA measured in the sample, wherein determining the patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment does not require measurement of a change in concentration of PSA measured in multiple patient samples as a function of time elapsed after the radical prostatectomy.
5-6. (canceled)
A method of determining a patient's prognosis for recurrence of prostate cancer, and/or determining a course of treatment for prostate cancer following a radical prostatectomy, comprising:
- performing an assay on at least one sample obtained from the patient following the radical prostatectomy to determine a measure of the concentration of prostate specific antigen (PSA) in the at least one sample;
- and
- determining the patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy based at least in part on the concentration of PSA measured in the at least one sample, wherein a measured concentration of PSA in the at least one sample greater than a threshold limit of no greater than about 10 pg/mL indicates a significant likelihood that the patient's prostate cancer will reoccur within 5 years.
8-12. (canceled)
(canceled)
(canceled)
(canceled)
33-49. (canceled)
Dependencies are inferred from the claim text.